D
Dan A. Dixon
High Impact
Professor
faculty
COM | Biochemistry & Molecular Biology
46 h-index
202 pubs
8,515 cited
Research Areas
Biography and Research Information
OverviewAI-generated summary
Dan A. Dixon's research focuses on the molecular mechanisms underlying cancer development and progression, with a particular emphasis on the role of RNA-binding proteins and extracellular vesicles. His work investigates how these components influence tumor microenvironments, promote cancer cell proliferation, and contribute to immunosuppression.
Dixon's group has published research on the function of specific RNA-binding proteins, such as HuR (ELAV1) and IMP1 (IGF2BP1), in posttranscriptional gene regulation within various cancer types, including colorectal and pancreatic cancer. His studies also explore the involvement of extracellular vesicles derived from cancer cells and from preclinical models in shaping the tumor microenvironment and activating signaling pathways like NF-κB, which can promote tumorigenic activities. Furthermore, his research has examined the therapeutic potential of existing drugs, such as pyrvinium pamoate, in targeting cancer cells under nutrient-depleted conditions by affecting mitochondrial function.
With a substantial publication record (over 200 publications) and a high citation count (over 8,400 citations), as indicated by his h-index of 46, Dixon is recognized as a highly cited researcher. He leads an active research group at the University of Arkansas for Medical Sciences, where he holds a professorship in the Department of Biochemistry and Molecular Biology.
Metrics
- h-index: 46
- Publications: 202
- Citations: 8,515
Selected Publications
-
Post-transcriptional regulation by HuR in colorectal cancer: impacts on tumor progression and therapeutic strategies (2025)
-
Suppression of stress granule formation is a vulnerability imposed by mutant p53 (2025)
Grants & Funding
- Nano-Engineered Lab-on-a-Chip for Assessing HuR-Regulated Exosomes for Cancer Monitoring and Targeted Therapy NIH/Nat. Cancer Institute - Pass Through: University of Kansas Principal Investigator
- Nano-Engineered Lab-on-a-Chip for Assessing HuR-Regulated Exosomes for Cancer Monitoring and Targeted Therapy NIH/Nat. Cancer Institute - Pass Through: University of Kansas Principal Investigator
- Nano-Engineered Lab-on-a-Chip for Assessing HuR-Regulated Exosomes for Cancer Monitoring and Targeted Therapy NIH/Nat. Cancer Institute - Pass Through: University of Kansas Principal Investigator
Collaboration Network
Top Collaborators
Ranjan Preet
University of Kansas (US)
21 shared publications
- CRC-derived exosomes containing the RNA binding protein HuR promote lung cell proliferation by stabilizing c-Myc mRNA
- The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- IMP1/IGF2BP1 in human colorectal cancer extracellular vesicles
- Regulation of autophagy by Rab27B in colorectal cancer
- Abstract 1370: Overexpression of the small GTPase Rab27B regulates autophagy flux and contributes to tumor growth in colorectal cancer
Showing 5 of 21 shared publications
Vikalp Vishwakarma
University of Kansas (US)
14 shared publications
- CRC-derived exosomes containing the RNA binding protein HuR promote lung cell proliferation by stabilizing c-Myc mRNA
- The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- Regulation of autophagy by Rab27B in colorectal cancer
- Abstract 1370: Overexpression of the small GTPase Rab27B regulates autophagy flux and contributes to tumor growth in colorectal cancer
- Fr563 THE RNA BINDING PROTEIN TRISTETRAPROLIN: A KEY FACTOR OF INTESTINAL CELL DIFFERENTIATION AND MICROBIAL HOMEOSTASIS IN COLORECTAL CANCER
Showing 5 of 14 shared publications
Avinoam Nevler
Thomas Jefferson University (US)
10 shared publications
- The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- The RNA-Binding Protein HuR Posttranscriptionally Regulates the Protumorigenic Activator YAP1 in Pancreatic Ductal Adenocarcinoma
- Data from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- Data from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- All supplemental figures tables and legends from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
Showing 5 of 10 shared publications
Austin Goetz
Thomas Jefferson University (US)
9 shared publications
- The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- Data from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- Data from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- All supplemental figures tables and legends from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- All supplemental figures tables and legends from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
Showing 5 of 9 shared publications
Sahida Afroz
University of Kansas (US)
8 shared publications
- Regulation of autophagy by Rab27B in colorectal cancer
- Abstract 1370: Overexpression of the small GTPase Rab27B regulates autophagy flux and contributes to tumor growth in colorectal cancer
- Su121 CHARACTERIZATION OF A ROLE FOR RAB27B IN AUTOPHAGY REGULATION IN COLORECTAL CANCER
- Abstract 3002: Characterization of novel role for Rab27B in autophagy regulation in colorectal cancer
- Sa1144: OVEREXPRESSION OF THE SMALL GTPASE RAB27B PROMOTES TUMOR GROWTH BY REGULATING AUTOPHAGY FLUX IN COLORECTAL CANCER
Showing 5 of 8 shared publications
Charles J. Yeo
Thomas Jefferson University (US)
8 shared publications
- The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- The RNA-Binding Protein HuR Posttranscriptionally Regulates the Protumorigenic Activator YAP1 in Pancreatic Ductal Adenocarcinoma
- Data from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- Data from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- Data from CRISPR Knockout of the HuR Gene Causes a Xenograft Lethal Phenotype
Showing 5 of 8 shared publications
Samantha Z. Brown
Oregon Health & Science University (US)
7 shared publications
- The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- The RNA-Binding Protein HuR Posttranscriptionally Regulates the Protumorigenic Activator YAP1 in Pancreatic Ductal Adenocarcinoma
- Data from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- Data from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- All supplemental figures tables and legends from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
Showing 5 of 7 shared publications
Jonathan R. Brody
Oregon Health & Science University (US)
7 shared publications
- Targeting the RNA-Binding Protein HuR in Cancer
- The RNA-Binding Protein HuR Posttranscriptionally Regulates the Protumorigenic Activator YAP1 in Pancreatic Ductal Adenocarcinoma
- Data from CRISPR Knockout of the HuR Gene Causes a Xenograft Lethal Phenotype
- Data from CRISPR Knockout of the HuR Gene Causes a Xenograft Lethal Phenotype
- Supplemental Figures and Tables from CRISPR Knockout of the HuR Gene Causes a Xenograft Lethal Phenotype
Showing 5 of 7 shared publications
Christopher W. Schultz
6 shared publications
- The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- The RNA-Binding Protein HuR Posttranscriptionally Regulates the Protumorigenic Activator YAP1 in Pancreatic Ductal Adenocarcinoma
- Data from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- Data from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- All supplemental figures tables and legends from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
Showing 5 of 6 shared publications
Grace A. McCarthy
6 shared publications
- The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- The RNA-Binding Protein HuR Posttranscriptionally Regulates the Protumorigenic Activator YAP1 in Pancreatic Ductal Adenocarcinoma
- Data from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- Data from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- All supplemental figures tables and legends from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
Showing 5 of 6 shared publications
Matthew McCoy
6 shared publications
- The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- The RNA-Binding Protein HuR Posttranscriptionally Regulates the Protumorigenic Activator YAP1 in Pancreatic Ductal Adenocarcinoma
- Data from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- Data from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- All supplemental figures tables and legends from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
Showing 5 of 6 shared publications
Aditi Jain
6 shared publications
- The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- The RNA-Binding Protein HuR Posttranscriptionally Regulates the Protumorigenic Activator YAP1 in Pancreatic Ductal Adenocarcinoma
- Data from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- Data from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- All supplemental figures tables and legends from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
Showing 5 of 6 shared publications
James B. DuHadaway
5 shared publications
- The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- Data from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- Data from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- All supplemental figures tables and legends from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- All supplemental figures tables and legends from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
Valerie Calvert
5 shared publications
- The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- Data from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- Data from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- All supplemental figures tables and legends from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- All supplemental figures tables and legends from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
Dezhen Wang
5 shared publications
- The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- Data from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- Data from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- All supplemental figures tables and legends from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
- All supplemental figures tables and legends from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
Similar Researchers
Based on overlapping research topics
A. Mazin Safar
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Immune Response and Inflammation
Cancer Treatment and Pharmacology
Md. Rafikul Islam
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
RNA research and splicing
Cancer Treatment and Pharmacology
Samuel L. Schach
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Immune Response and Inflammation
Cancer Treatment and Pharmacology
lan J Tackett
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Immune Response and Inflammation
Cancer Treatment and Pharmacology
Haya Safar
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Immune Response and Inflammation
Molecular Biology Techniques and Applications
Yuntao Dai
University of Arkansas at Fayetteville
Cancer-related molecular mechanisms research
Cancer Treatment and Pharmacology
Molecular Biology Techniques and Applications